Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310

Summary

CTX310, a CRISPR-Cas9 gene editing therapy targeting ANGPTL3, has results on durability published in the New England Journal of Medicine, demonstrating ongoing clinical development of this approach.